학술논문
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
Document Type
Article
Author
Source
In: The Lancet Oncology . (The Lancet Oncology, June 2024, 25(6):707-719)
Subject
Language
English
ISSN
14745488
14702045
14702045